Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G E Adams

Showing results (131-140 of 163) with videos related to

Pageof 17
Sort By:
The British Journal of Cancer. Supplement|July 1, 1996
Effect of hydralazine in spontaneous tumours assessed by oxygen electrodes and 31P-magnetic resonance spectroscopyM Nordsmark, R J Maxwell, P J Wood, et al.
Journal of Medicinal Chemistry|September 18, 1992
2-Nitroimidazole dual-function bioreductive drugs: studies on the effects of regioisomerism and side-chain structural modifications on differential cytotoxicity and radiosensitization by aziridinyl and oxiranyl derivativesM A Naylor, M D Threadgill, P Webb, et al.
International Journal of Radiation Oncology, Biology, Physics|July 1, 1986
Studies on the mechanisms of the radiosensitizing and cytotoxic properties of RSU-1069 and its analoguesJ M Walling, I J Stratford, G E Adams, et al.
International Journal of Radiation Oncology, Biology, Physics|January 1, 1992
Dual function nitroimidazoles less toxic than RSU 1069: selection of candidate drugs for clinical trial (RB 6145 and/or PD 130908S Cole, I J Stratford, E M Fielden, et al.
International Journal of Radiation Oncology, Biology, Physics|July 1, 1986
Analogues of RSU-1069: radiosensitization and toxicity in vitro and in vivoI Ahmed, T C Jenkins, J M Walling, et al.
Biochemical and Biophysical Research Communications|October 4, 1976
Mammalian cell toxicity of nitro compounds : dependence upon reduction potentialG E Adams, E D Clarke, R S Jacobs, et al.
International Journal of Radiation Oncology, Biology, Physics|May 15, 1994
Pharmacokinetics, metabolism and distribution of 1,2-dihydro-8-(4-methylpiperazinyl)-4-phenylimidazo [1,2-A] pyrido [3,2-E] pyrazine-5-oxide in C3H miceB M Sutton, N J Reeves, M A Naylor, et al.
International Journal of Radiation Biology|July 1, 1991
Monitoring metabolic responses after induction of hypoxia in the KHT tumour using 31P NMR spectroscopyJ C Bremner, C J Counsell, H S Edwards, et al.
British Journal of Cancer|November 1, 1991
In vivo 31P nuclear magnetic resonance spectroscopy of experimental murine tumours and human tumour xenografts: effects of blood flow modificationJ C Bremner, C J Counsell, G E Adams, et al.
Acta Oncologica (Stockholm, Sweden)|January 1, 1996
A comparison of the physiological effects of RSU1069 and RB6145 in the SCCVII murine tumourP J Wood, M R Horsman, A A Khalil, et al.
Pageof 17

Showing results (131-140 of 163) with videos related to

Sort By:
Pageof 17
The British Journal of Cancer. Supplement|July 1, 1996
Effect of hydralazine in spontaneous tumours assessed by oxygen electrodes and 31P-magnetic resonance spectroscopyM Nordsmark, R J Maxwell, P J Wood, et al.
Journal of Medicinal Chemistry|September 18, 1992
2-Nitroimidazole dual-function bioreductive drugs: studies on the effects of regioisomerism and side-chain structural modifications on differential cytotoxicity and radiosensitization by aziridinyl and oxiranyl derivativesM A Naylor, M D Threadgill, P Webb, et al.
International Journal of Radiation Oncology, Biology, Physics|July 1, 1986
Studies on the mechanisms of the radiosensitizing and cytotoxic properties of RSU-1069 and its analoguesJ M Walling, I J Stratford, G E Adams, et al.
International Journal of Radiation Oncology, Biology, Physics|January 1, 1992
Dual function nitroimidazoles less toxic than RSU 1069: selection of candidate drugs for clinical trial (RB 6145 and/or PD 130908S Cole, I J Stratford, E M Fielden, et al.
International Journal of Radiation Oncology, Biology, Physics|July 1, 1986
Analogues of RSU-1069: radiosensitization and toxicity in vitro and in vivoI Ahmed, T C Jenkins, J M Walling, et al.
Biochemical and Biophysical Research Communications|October 4, 1976
Mammalian cell toxicity of nitro compounds : dependence upon reduction potentialG E Adams, E D Clarke, R S Jacobs, et al.
International Journal of Radiation Oncology, Biology, Physics|May 15, 1994
Pharmacokinetics, metabolism and distribution of 1,2-dihydro-8-(4-methylpiperazinyl)-4-phenylimidazo [1,2-A] pyrido [3,2-E] pyrazine-5-oxide in C3H miceB M Sutton, N J Reeves, M A Naylor, et al.
International Journal of Radiation Biology|July 1, 1991
Monitoring metabolic responses after induction of hypoxia in the KHT tumour using 31P NMR spectroscopyJ C Bremner, C J Counsell, H S Edwards, et al.
British Journal of Cancer|November 1, 1991
In vivo 31P nuclear magnetic resonance spectroscopy of experimental murine tumours and human tumour xenografts: effects of blood flow modificationJ C Bremner, C J Counsell, G E Adams, et al.
Acta Oncologica (Stockholm, Sweden)|January 1, 1996
A comparison of the physiological effects of RSU1069 and RB6145 in the SCCVII murine tumourP J Wood, M R Horsman, A A Khalil, et al.
Pageof 17